Page 1 - Dyslipidaemia for programming
P. 1
REFLECTIONS dae mia
Dyslipidaemia Global Newsletter #3
TABLE OF CONTENTS Dyslipiad
On behalf of the Scientific Planning Committee (SPCD)y, swliepi
KEY ARTICLES
would like to welcome you back to the third newsletter in our
Statin use for the primary prevention of cardiovascular series where we summarize the latest clinical and real-world
disease in adults: US preventive services task force evidence in the field of dyslipidaemia and reflect on the clinical
recommendation statement. US Preventive Services Task impact of these data on dyslipidaemia management. As
Force, Mangione CM, et al. JAMA. 2022 Aug 23;328(8):746- always, we invite you to interact with this newsletter through
753. links to podcasts, resource tools, or commentaries, or viewing
short clinical perspectives from our SPC, and delve into the
Long-term secondary prevention of cardiovascular articles through hyperlinks for in-depth study.
disease with a Mediterranean diet and a low-fat diet
(CORDIOPREV): A randomised controlled trial. Delgado- Prof. Farnier (Chair)
Lista J, et al. Lancet. 2022;399:1876-85.
SCIENTIFIC PLANNING COMMITTEE
Long-term efficacy and safety of moderate-intensity statin
with ezetimibe combination therapy versus high-intensity Prof. Michel Farnier Prof. Augusto Lavalle
statin monotherapy in patients with atherosclerotic (France) Cobo
cardiovascular disease (RACING): A randomised, open- Prof. Miriam Sandín (Argentina)
label, non-inferiority trial. Kim BK, et al. Lancet. 2022 Jul (Spain) Prof. Lourdes Santos
30;400(10349):380-390. (Philippines)
Intensity of and adherence to lipid-lowering therapy as Prof. Marcin Welnicki
predictors of major adverse cardiovascular outcomes in (Poland)
patients with coronary heart disease. Mazhar F, et al. J Am
Heart Assoc. 2022 Jul 19;11(14):e025813.
Polypill strategy in secondary cardiovascular prevention.
Castellano JM, et al. N Engl J Med. 2022;387 :967-77.
Long-term evolocumab in patients with established
atherosclerotic cardiovascular disease. O’Donoghue
ML, et al. J Circulation. 2022 Aug 29. doi: 10.1161/
CIRCULATIONAHA.122.061620. Online ahead of print.
ADDITIONAL ARTICLES OF INTEREST
Statin use for the primary prevention of cardiovascular disease in adults: US
preventive services task force recommendation statement.
US Preventive Services Task Force, Mangione CM, et al. JAMA. 2022 Aug 23;328(8):746-753.
Cardiovascular disease (CVD) is the leading cause of mortality person’s 10-year risk of a CVD event, the greater the chance of
in the US, accounting for more than one in four deaths. In 2019, benefit from statin use.
there were an estimated 558,000 deaths caused by coronary
heart disease and 109,000 deaths caused by ischemic stroke. To implement the recommendations, the USPSTF suggests
The US Preventive Services Task Force (USPSTF) has updated considering the patient’s age first. For adults aged 40 to 75
its 2016 recommendations based on a review of the evidence years, determine whether the patient has a cardiovascular risk
on the benefits and harms of statins for reducing CVD-related factor (dyslipidaemia, diabetes, hypertension, or smoking) and
morbidity or mortality or all-cause mortality. estimate the CVD risk using a CVD risk estimator. In patients
who have a cardiovascular risk factor and an estimated 10-
The likelihood that a patient will benefit from statin use depends year CVD risk of 10% or greater, the USPSTF recommends
on their absolute risk of having a future CVD event. The higher a initiating a moderate-intensity statin after discussing the
